All News Items

Elizabeth Ramirez-Washka, JD, associate general counsel for Duke University and Duke University Health System, credits her grandparents with teaching her to work hard, value education, and pay it forward. Those lessons have guided her from advocating for her family while growing up in Texas to creating opportunities for others at Duke and beyond.

New research from Duke University School of Medicine points to a surprising possibility: a naturally occurring human gut bacterium produces a sugar molecule that helps obese mice increase energy expenditure and reduce visceral fat that accumulates around internal organs and is associated with diabetes and heart disease.

A discovery that began in a Duke laboratory is now being tested in Duke patients, offering a potential new approach to diagnosing cardiac sarcoidosis, which can be life-threatening and difficult to diagnose.

Duke researchers are leading a phase I clinical trial to evaluate a new experimental treatment for glioblastoma, one of the most aggressive and deadly forms of brain cancer. The drug is a type of immunotherapy known as a Brain Bispecific T-cell Engager (BRiTE), which is designed to cross the blood-brain barrier and to help the patient’s own immune cells (T-cells) recognize and attack cancer cells. 

A team led by Duke neonatologist Noelle Younge, MD, MHS, has found evidence that the intestinal microbiome plays a direct role in slow weight gain and poor growth in preterm infants.

A nationally recognized leader in quality and safety, Richard P. Shannon, MD, and his family's support of the Duke Health Patient Care Fund reflects their belief that even small acts of generosity can have a lasting impact, helping Duke Health respond to immediate patient needs while advancing innovation and enhancing care for patients and families.

This story was originally published on the DCRI website

A surgical team at Duke Health has performed the first U.S. implantation of a new remote-controlled artificial urinary sphincter that aims to give men who struggle with incontinence after treatment for pelvic cancers a more personalized and discreet way to manage bladder control.

David Tuveson, MD, PhD, will join Duke Health as executive director of the Duke Cancer Institute (DCI), effective October 31, 2026.  Tuveson, a preeminent cancer biologist, is currently the Roy J. Zuckerberg Professor of Cancer Research and director of the National Cancer Institute-Designated Cancer Center at Cold Spring Harbor Laboratory. He is also the chief scientist for the Lustgarten Foundation for Pancreatic Cancer Research.

Duke is building the tools to catch heart disease before patients know they have it.